| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into. |
businesswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle® Radioconjugates (BRC®). |
businesswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted |
Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses. |
seekingalpha.com |
2025-04-22 07:47:37 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. |
businesswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. |
businesswire.com |
2025-03-05 09:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. “In 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati. |
businesswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. |
businesswire.com |
2025-02-03 18:05:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data |
Bicycle Therapeutics' BT8009 showed promising efficacy and safety in early trials, but mixed results in combination with Keytruda caused significant stock volatility. BT8009 demonstrated a superior safety profile compared to PADCEV, with fewer and milder adverse events due to its shorter half-life and faster elimination. Financially, BCYC is solid with $890 million in cash, providing a runway of 11-12 quarters, though it trades at cash value. |
seekingalpha.com |
2025-02-02 07:26:16 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and. |
businesswire.com |
2025-01-13 09:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentat. |
businesswire.com |
2025-01-09 09:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the company's Board of Directors granted to 12 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 67,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i. |
businesswire.com |
2025-01-03 18:05:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The. |
businesswire.com |
2024-12-12 20:30:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on December 2, 2024, the Compensation Committee of the company's Board of Directors granted to thirteen new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 62,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees ent. |
businesswire.com |
2024-12-02 18:05:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABCS. |
businesswire.com |
2024-11-25 19:30:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern |
Today, we revisit Bicycle Therapeutics plc, a clinical-stage biopharma firm, that has intriguing potential and focuses on developing medicines for unmet needs. The company is advancing several candidates within its pipeline and is well-funded into mid-2027. The stock also continues to enjoy strong analyst firm support. An updated analysis of Bicycle Therapeutics follows in the paragraphs below. |
seekingalpha.com |
2024-11-07 12:04:39 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on November 1, 2024, the Compensation Committee of the company's Board of Directors granted to twelve new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 56,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees enter. |
businesswire.com |
2024-11-01 18:05:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the third quarter ended September 30, 2024. “In the third quarter, we continued to make significant advancements across our business and pipeline. At ESMO, we reported updated data for our clinical-. |
businesswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrating the positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use, as we. |
businesswire.com |
2024-10-23 11:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place. |
businesswire.com |
2024-10-16 11:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? |
Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-10-14 10:40:16 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 |
BARCELONA--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated Phase 1/2 clinical results for Bicycle Toxin Conjugate (BTC®) zelenectide pevedotin (formerly BT8009) in metastatic urothelial cancer (mUC); BTC molecule BT5528 in advanced solid tumors, such as mUC and ovarian; and Bicycle Tumor-Targeted Immune Cell Agonist. |
businesswire.com |
2024-09-14 07:00:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone |
RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond. |
benzinga.com |
2024-09-06 17:37:16 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Is Looking Increasingly Attractive |
Bicycle Therapeutics, founded by Nobel laureate Dr. Greg Winter, uses "bicycles", which are smaller, more stable, and cheaper to produce than monoclonal antibodies. BCYC's pipeline includes promising BTC molecules targeting various tumors with differentiated safety profiles and efficacy data. Financially, BCYC has a market cap of $1.54bn, a strong cash balance, an extensive IP portfolio, and collaborations with major pharma companies, making it an attractive investment opportunity. |
seekingalpha.com |
2024-08-20 11:37:25 |
Czytaj oryginał (ang.) |
| What Makes Bicycle Therapeutics (BCYC) a New Buy Stock |
Bicycle Therapeutics (BCYC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-08-09 17:01:17 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 88.9% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-08-09 14:55:37 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC) today announced that on August 1, 2024, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 71,200 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. |
businesswire.com |
2024-08-01 20:05:00 |
Czytaj oryginał (ang.) |
| Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024 |
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13-17 in Barcelona. Poster Presentation Details: Title: BT8009 monotherapy in enfortumab vedotin-naïv. |
businesswire.com |
2024-07-22 11:00:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year? |
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year. |
zacks.com |
2024-06-27 14:40:45 |
Czytaj oryginał (ang.) |
| Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio |
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX. |
zacks.com |
2024-06-21 13:25:24 |
Czytaj oryginał (ang.) |
| Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year? |
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year. |
zacks.com |
2024-06-11 14:40:41 |
Czytaj oryginał (ang.) |